# Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

> **NCT05601830** · PHASE1 · TERMINATED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 1 (actual)

## Conditions studied

- Minimal Residual Disease

## Interventions

- **DRUG:** QN-030a
- **DRUG:** Cyclophosphamid
- **DRUG:** Fludarabine
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT05601830
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-09
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** It did not reach the expected results of clinical trial
- **Last updated:** 2024-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05601830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05601830, "Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05601830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*